Global pharmaceutical firms are paying upfront to secure technology transfer deals with Alteogen, as demand for its subcutaneous injection platform surges; Shinhan Investment maintains a 730,000 won target price, citing strong licensing prospects despite recent patent litigation.
#YonhapInfomax #Alteogen #TechnologyTransfer #ShinhanInvestment #OptionAgreement #TargetPrice730000Won #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=97468







